Form 4: BioXcel Therapeutics Director Acquires Stock Options

Michael Patrick Miller, a director of BioXcel Therapeutics, acquired stock options exercisable for 17,000 shares of common stock.

Summary

• On June 10, 2024, Michael Patrick Miller, a director of BioXcel Therapeutics, Inc., was granted stock options to purchase 17,000 shares of common stock.
• The exercise price of the options is $1.44 per share.
• The options vest on the earlier of June 10, 2025, or the day before the next annual meeting of the Issuer's stockholders after the grant date, contingent upon continued service as a non-employee director.
• The options expire on June 10, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine filing. The grant of options to a director is generally viewed as a positive, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, stock options, director, Form 4, Michael Patrick Miller, insider trading